Clinical Trials Database

Trial Name	Trial ID	Main Coordinating Centre and contact	Status Recruitment	Topic	Participants
CIRCA DIEM	ACTRN12618000371291p	Jane Pillow +61417621960 jane.pillow@uwa.edu.au The University of Western Australia	Not yet recruiting IMPACT endorsed	Newborn – developmental	Babies born at < 31 weeks and 6 days postmenstrual age. Have initial care at a perinatal centre where routine care does not include individual environmental light/noise cycling.
DIAMOND - DIfferent Approaches to MOderate & later preterm Nutrition: Determinants of feed tolerance, body composition and development	ACTRN12616001199404	Liggins Institute, University of Auckland t.alexander@auckland.ac.nz	Currently recruiting IMPACT endorsed	Newborn nutrition Newborn body composition Neurodevelopment	Preterm babies between 32+0 - 35+6 admitted to the neonatal unit requiring IV insertion
EPPI Trial - Enoxaparin for the Prevention of Preeclampsia and Intrauterine growth restriction ? a pilot randomised placebo-controlled trial	ACTRN12609000699268	Department of Obstetrics and Gynaecology, University of Auckland. Laura Mackay (Trial Manager) laura.mackay@auckland.ac.nz; Dr Katie Groom (Chief Investigator) k.groom@auckland.ac.nz	Recruitment complete IMPACT reviewed	Fetal growth. Preeclampsia	Women with previous pregnancy complicated by early onset preeclampsia or fetal growth restriction
LIFT - Lactoferrin Infant Feeding Trial to prevent sepsis and death in preterm infants	ACTRN12611000247976	NHMRC Clinical Trial Centre, NSW lift@ctc.usyd.edu.au	Currently recruiting IMPACT reviewed
MAGENTA - Does antenatal magnesium sulphate given to women at risk of preterm birth between 30 and 34 weeks' gestation reduce the risk of death or cerebral palsy in their children? - a randomised controlled trial.	ACTRN126110000491965	University of Adelaide, Clinical Trial Manager Pat Ashwood +61 8 8161 7767	Currently recruiting IMPACT reviewed	Neuroprotection, Antenatal magnesium sulphate, Cerebral palsy	Women at risk of preterm birth between 30 and 34 weeks’ gestation where birth is planned or definitely expected within 24 hours, have a singleton or twin pregnancy, no contraindications to the use of antenatal magnesium sulphate
MBM - My Baby’s Movements: a stepped wedge cluster randomised controlled trial to raise maternal awareness of fetal movements during pregnancy	ACTRN12614000291684	Mater Research Institute - The University of Queensland u.chandrasiri@mater.uq.edu.au	Not yet recruiting IMPACT endorsed	Stillbirth prevention. Fetal surveillance. Parental social and emotional wellbeing.	Pregnant women without any congenital abnormalities
N3RO - Can omega 3 fatty acids improve respiratory outcomes in preterm infants?	ACTRN12612000503820	Women's & Children's Health Research Institute carmel.collins@health.sa.gov.au	Recruitment complete IMPACT reviewed	Newborn respiratory	Born at less than 29 weeks gestational age, within 3 days of commencing enteral feeds
PAEAN - Preventing Adverse Outcomes of Neonatal Hypoxic Ischaemic Encephalopathy with Erythropoietin: a randomised placebo controlled multicentre clinical trial	ACTRN12614000669695	NHMRC Clinical Trials Centre, University of Sydney paean@ctc.usyd.edu.au +61 2 9562 5000	Currently recruiting IMPACT reviewed	Newborn – developmental
POP-OUT - Persistent Occiput Posterior: OUTcomes following manual rotation	ACTRN12612001312831	Royal Prince Alfred Hospital, NSW hala.phipps@email.cs.nsw.gov.au	Recruitment complete IMPACT reviewed	Labour and intrapartum care
PROTECT - Can Pentoxifylline improve long-term outcomes in preterm infants with late-onset sepsis or necrotizing enterocolitis? A pragmatic, randomized, controlled trial	ACTRN12616000405415	NHMRC Clinical Trial Centre, NSW protect@ctc.usyd.edu.au	Currently recruiting IMPACT reviewed	Preterm infant sepsis and inflammation, neurodevelopment	Born at less than 29 weeks gestational age with suspected late-onset sepsis or necrotizing enterocolitis
PROVIDE - Impact of Protein IVN on Development: for extremely low birthweight babies, does higher intravenous protein intake in the first 5 days after birth improve neurodevelopmental outcome, growth and body composition through to 2 years of age?	ACTRN12612001084875	Liggins Institute, University of Auckland, Barbara Cormack bcormack@adhb.govt.nz	Currently recruiting IMPACT reviewed	Protein, intravenous nutrition, neurodevelopment	Birthweight <1000 g
STRIDER (NZAus)- A randomised placebo-controlled trial of a new therapy (sildenafil) to help growth in severely growth restricted fetuses at very early gestations	ACTRN12612000584831	Department of Obstetrics and Gynaecology, University of Auckland Laura Mackay (Trial Manager) laura.mackay@auckland.ac.nz; Dr Katie Groom (Chief Investigator) k.groom@auckland.ac.nz	Recruitment complete IMPACT reviewed	Fetal growth. Preeclampsia. Pterterm birth - prevention and treatment	Women with pregnancies complicated early onset fetal growth restriction. Abdominal circumference ≤3rd centile at 22-28 weeks or EFW <700g at 28-80 weeks
The PROTECT Me trial	RES-17-0000-583A	Monash Medical Centre Clayton Dr Kirsten Palmer kirsten.palmer@monash.edu	Currently recruiting IMPACT endorsed	Early onset Intrauterine Fetal Growth Restriction	Women with pregnancies complicated by severe fetal growth restriction between 23+0 and 31+6 weeks gestation